Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Payables (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Payables for 13 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 52.2% to $2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 52.2% increase, with the full-year FY2024 number at $2.2 million, changed N/A from a year prior.
  • Payables was $2.2 million for Q3 2025 at Theravance Biopharma, up from $1.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $10.7 million in Q2 2021 to a low of $1.5 million in Q3 2024.
  • A 5-year average of $3.4 million and a median of $2.2 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 77.9% in 2022, then surged 76.36% in 2023.
  • Theravance Biopharma's Payables stood at $8.9 million in 2021, then tumbled by 82.54% to $1.6 million in 2022, then skyrocketed by 52.38% to $2.4 million in 2023, then dropped by 5.32% to $2.2 million in 2024, then decreased by 1.29% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Payables are $2.2 million (Q3 2025), $1.7 million (Q2 2025), and $2.4 million (Q1 2025).